157 related articles for article (PubMed ID: 26398246)
1. Secondary Resistance to Vismodegib After Initial Successful Treatment of Extensive Recurrent Periocular Basal Cell Carcinoma with Orbital Invasion.
Papastefanou VP; René C
Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S68-S70. PubMed ID: 26398246
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.
Demirci H; Worden F; Nelson CC; Elner VM; Kahana A
Ophthalmic Plast Reconstr Surg; 2015; 31(6):463-6. PubMed ID: 25675162
[TBL] [Abstract][Full Text] [Related]
3. Vismodegib for periocular and orbital basal cell carcinoma.
Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
[TBL] [Abstract][Full Text] [Related]
4. Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.
Pollom EL; Bui TT; Chang AL; Colevas AD; Hara WY
JAMA Dermatol; 2015 Sep; 151(9):998-1001. PubMed ID: 25874733
[TBL] [Abstract][Full Text] [Related]
5. Indications and limitations of vismodegib for basal cell carcinoma.
Yin VT; Sniegowski M; Esmaeli B
JAMA Ophthalmol; 2014 Jul; 132(7):905-6. PubMed ID: 25010179
[No Abstract] [Full Text] [Related]
6. Indications and limitations of vismodegib for basal cell carcinoma--reply.
Gill HS; Moscato EE; Silkiss RZ
JAMA Ophthalmol; 2014 Jul; 132(7):906. PubMed ID: 25010181
[No Abstract] [Full Text] [Related]
7. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
[TBL] [Abstract][Full Text] [Related]
8. Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma.
Brinkhuizen T; Reinders MG; van Geel M; Hendriksen AJ; Paulussen AD; Winnepenninckx VJ; Keymeulen KB; Soetekouw PM; van Steensel MA; Mosterd K
J Am Acad Dermatol; 2014 Nov; 71(5):1005-8. PubMed ID: 25199678
[No Abstract] [Full Text] [Related]
9. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.
Axelson M; Liu K; Jiang X; He K; Wang J; Zhao H; Kufrin D; Palmby T; Dong Z; Russell AM; Miksinski S; Keegan P; Pazdur R
Clin Cancer Res; 2013 May; 19(9):2289-93. PubMed ID: 23515405
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma.
Yin VT; Pfeiffer ML; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2013; 29(2):87-92. PubMed ID: 23446297
[TBL] [Abstract][Full Text] [Related]
11. Epidermal cyst formation and hyperkeratosis in a patient treated with vismodegib for locally advanced Basal cell carcinoma.
Reinders MG; Brinkhuizen T; Soetekouw PM; Kelleners-Smeets NW; Hamid MA; Mosterd K
Acta Derm Venereol; 2015 May; 95(5):618-9. PubMed ID: 25425396
[No Abstract] [Full Text] [Related]
12. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
13. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
Lyseng-Williamson KA; Keating GM
Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
[TBL] [Abstract][Full Text] [Related]
14. Regression of a basal cell carcinoma infiltrating the brain after vismodegib therapy.
Kaehler KC; Gutzmer R; Egberts F; Hauschild A
J Dtsch Dermatol Ges; 2014 Oct; 12(10):906-7. PubMed ID: 25041591
[No Abstract] [Full Text] [Related]
15. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
Meani RE; Lim SW; Chang AL; Kelly JW
Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162
[TBL] [Abstract][Full Text] [Related]
16. Vismodegib in basal cell carcinoma.
Amaria RN; Bowles DW; Lewis KD; Jimeno A
Drugs Today (Barc); 2012 Jul; 48(7):459-67. PubMed ID: 22844657
[TBL] [Abstract][Full Text] [Related]
17. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome.
Ozgur OK; Yin V; Chou E; Ball S; Kies M; William WN; Migden M; Thuro BA; Esmaeli B
Am J Ophthalmol; 2015 Aug; 160(2):220-227.e2. PubMed ID: 25935097
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical markers of advanced basal cell carcinoma: CD56 is associated with a lack of response to vismodegib.
Castillo JM; Knol AC; Nguyen JM; Khammari A; Saint-Jean M; Dreno B
Eur J Dermatol; 2016 Oct; 26(5):452-459. PubMed ID: 27346829
[TBL] [Abstract][Full Text] [Related]
19. Vismodegib (ERIVEDGE°) In basal cell carcinoma: too many unknowns.
Prescrire Int; 2015 Jan; 24(156):11-4. PubMed ID: 25729822
[TBL] [Abstract][Full Text] [Related]
20. Vismodegib resistance in basal cell carcinoma: not a smooth fit.
Ridky TW; Cotsarelis G
Cancer Cell; 2015 Mar; 27(3):315-6. PubMed ID: 25759014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
